Navigation Links
Trio of drugs may combat 'triple negative' breast cancer
Date:12/10/2010

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. The information is embargoed for the time of presentation at the symposium.

TRIO OF DRUGS MAY COMBAT "TRIPLE NEGATIVE" BREAST CANCER
(Presentation # PD01-05)

Working with cell cultures and mouse models, researchers at the Johns Hopkins Kimmel Cancer Center have tested a cocktail of three drugs that holds promise for treating so-called triple negative breast cancers.

Women with such cancers lack all three hormone receptors estrogen, progesterone and human epidermal growth factor 2 (HER2). Currently, treatments for triple negative breast cancers are limited to surgery, chemotherapy and radiation, which provide some improvements but overall poor prognoses.

In the new study, Johns Hopkins scientists began with a drug called Entinostat, which blocks an enzyme that unfolds DNA, providing regulatory molecules access to genes within and also reactivates a gene called retinoic acid receptor-beta (RARβ). Then, they added a drug called All Trans Retinoic Acid (ATRA), related to Vitamin A, which binds a protein made by the reactivated RARβ gene. Together, the ATRA drug and RARβ gene act as a brake on cancer cell growth. The scientists completed the drug cocktail with conventional chemotherapy using either low doses of doxorubicin or paclitaxel.

According to the scientists, each of the three drugs used alone may have some effect on killing tumors cells, but combining them tips the scale in favor of killing more cells.

Tests on laboratory-cultured cells showed that the triple combo therapy halted the growth of multiple triple negative breast cancer cell lines more effectively than any one of the treatments alone. The combined therapy also rejuvenated the expression of RARβ, and strongly inhibited tumor growth in three-quarters of mice engrafted with breast tumor cells.

The researchers are discussing potential clinical trials of the combo therapy, which they hope to start in the next year, says Nguyen K. Nguyen, a graduate student in the Cellular and Molecular Medicine Program at Johns Hopkins.


'/>"/>

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Drugs are safe, active in patients normally ineligible for clinical trial
2. Certain Breast Cancer Drugs Linked With Heart Risks in Older Women
3. Economist honored for study on impact of new cancer drugs on life expectancy
4. FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer
5. FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
6. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
7. No Link Between Heartburn Drugs and Birth Defects: Study
8. Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests
9. Taking a break from osteoporosis drugs can protect bones
10. Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
11. Aortic aneurysm treatable with asthma drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare & Medicaid Services ... Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid for ... part of the Administration’s effort to build a system that delivers better care and ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the ... Congressional political games that circumvent health needs of over 30 million. Many interviews with ... anxieties and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... ... January 19, 2017 , ... With the cold weather here, many people will have ... are efficient when clearing large amounts of snow, but they can be dangerous when used ... Consumer Product Safety Commission for the proper use of snow blowers:, , ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... for Leading Companies – our new study reveals trends, ... issues and events affecting the Alzheimer,s disease therapeutics and ... answer these key questions: - How is the Alzheimer,s ...
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... , January 19, 2017 ... ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... Published recently in a ... peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology: